Skip to main content

Table 2 Correlation of topoisomerase isoenzymes with clinical stage of all EOC patients

From: Targeting of topoisomerases for prognosis and drug resistance in ovarian cancer

Topoisomerases Clinical stages Case-low Case-high HR (%95 CI) P-value
TOP1 I 19 55 4.47 (0.57 − 34.8) 0.12
  II 43 16 2.54 (0.81 − 7.91) 0.096
  III 718 264 1.18 (0.97 − 1.42) 0.096
  IV 69 97 1.17 (0.8 − 1.71) 0.43
TOP2A I 37 37 10.37 (3.04−35.44) 5.8e − 06
  II 25 34 2.04 (0.68 − 6.11) 0.19
  III 277 705 1.21 (1−1.46) 0.053
  IV 74 92 0.76 (0.52 − 1.13) 0.18
TOP2B I 34 40 4.64 (1.02 − 21.21) 0.029
  II 24 35 0.29 (0.09 − 0.94) 0.028
  III 249 719 0.87 (0.72 − 1.06) 0.18
  IV 94 72 1.4 (0.96 − 2.06) 0.082
TOP3A I 54 20 1.84 (0.58 − 5.8) 0.29
  II 42 17 0.44 (0.1 − 1.98) 0.27
  III 716 266 0.7 (0.57 − 0.86) 0.00045
  IV 59 107 0.74 (0.5 − 1.09) 0.13
TOP3B I 42 32 3.05 (0.91 − 10.2) 0.057
  II 35 24 1.76 (0.58 − 5.33) 0.31
  III 675 307 0.75 (0.63 − 0.91) 0.003
  IV 64 102 0.73 (0.5 − 1.08) 0.11
  1. Abbreviation: HR hazard ratio; CI confidence interval